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GBV-C/HGV in hemodialysis patients: Anti-E2 antibodies and GBV-C/
HGV-RNA in serum and peripheral blood mononuclear cells. Hepatitis G
virus (GBV-C/HGV), a recently identified RNA virus adds to the risk of
parenteral transmitted viral infections in hemodialysis patients. We stud-
ied the prevalence of GBV-C/HGV-RNA in serum and peripheral blood
mononuclear cells (PMNC) by reverse transcription-polymerase chain
reaction (RT-PCR) and determined antibodies against the envelope
protein E2 of GBV-C/HGV by ELISA. A total of 119 dialysis patients
were studied. GBV-C/HGV-RNA was found in 16 of 119 patients (13%)
as compared with 2% of healthy controls (P 5 0.014). Two of the 16
GBV-C/HGV-RNA1 patients were co-infected with HCV, and none was
positive for HBV-DNA. In 38% of serum GBV-C/HGV-RNA1 patients
GBV-C/HGV-RNA was also detected in PMNC. In addition, GBV-C/
HGV-RNA was identified in PMNC of 2 patients negative for GBV-C/
HGV-RNA in serum. Twenty-four patients had anti-E2 antibodies in
serum (20%), but were GBV-C/HGV-RNA2. In addition, two of the 16
GBV-C/HGV-RNA1 patients were concomitantly positive for anti-E2
antibodies. Only one of the 16 GBV-C/HGV infected patients had
elevated aminotransferases; this patient was co-infected with hepatitis C
virus. GBV-C/HGV-RNA positivity was independent on duration of
hemodialysis, but GBV-C/HGV-RNA1 patients had received more units
of blood in the past. Combined data of past contact, as assessed by anti-E2
antibodies, and present infection, documented by GBV-C/HGV-RNA,
indicate a high overall exposure to GBV-C/HGV in dialysis patients.
Patients undergoing chronic intermittent hemodialysis carry a
variable risk for acquiring parenterally transmitted infections such
as hepatitis B (HBV) or hepatitis C (HCV) [1]. With HBV
infection still present but less prevalent in that group (5.6%) [1],
the growing impact of HCV infection has been documented in
several surveys showing seroprevalence rates from 8% to 55% [2,
3].
Recently, a new RNA virus belonging to the family of Flaviviri-
dae has been identified by two groups [4, 5]. This virus has been
shown to be associated with hepatitis and transmitted parenterally
and is now commonly referred as GBV-C/HGV hepatitis virus [6].
GBV-C/HGV has been shown to be associated with infections of
other parenterally transmitted viruses such as HBV or HCV [5, 7].
In addition to being present in serum HGV-RNA has also been
found in PMNC [8]. In case of HBV and HCV, we reported
previously that investigating PMNC for the presence of viral
genomes can be useful in the positive identification of additional
potential infectious patients [9].
To study the infection of GBV-C/HGV in hemodialysis pa-
tients, we used reverse transcription polymerase chain reaction
(RT-PCR) to assess the prevalence of GBV-C/HGV-RNA in
serum. As GBV-C/HGV has been detected in lymphocytes we
also looked for the presence of GBV-C/HGV-RNA in PMNC. In
addition, we determined antibodies against the envelope protein
of GBV-C/HGV (anti-E2) by ELISA as a marker of resolved
infection with GBV-C/HGV. We report that GBV-C/HGV-RNA
can be found in serum of 13% of hemodialysis patients and that in
some infected patients GBV-C/HGV-RNA can only be found in
PMNC, but not in serum. In addition, 20% of the patients had had
past contact with GBV-C/HGV, as judged by the presence of
anti-E2.
METHODS
Patients
We investigated 119 patients (69 male, 50 female, mean 53 6 17
years) undergoing chronic hemodialysis at the dialysis units of the
Universita¨tsklinik fu¨r Innere Medizin III, University of Vienna.
Mean duration of dialysis was 35 6 32 months. Renal disorders
resulting in end-stage kidney disease were glomerulonephritis (27
patients), diabetic nephropathy (18 patients), analgesic nephrop-
athy (7 patients), interstitial nephritis (15 patients) and miscella-
neous causes (16 patients). The etiology of end-stage renal disease
could not be established in 36 patients. In regular intervals (every
3 months) infection with hepatitis virus B or C was checked by
serologic methods. Serologic determinations of HBV markers
(HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe; Abbott Labora-
tories) and of HCV markers (anti-HCV antibody, 3rd generation;
Abbott Laboratories) were performed by the ELISA method
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using commercially available kits. None of the patients was
HBsAg1, and 26 patients had markers of past HBV infection
(antiHBc1). Seventy-eight patients were antiHBs1, either by
natural infection or as a result of vaccination with a recombinant
hepatitis B vaccine (Engerix; Smith Kline Beecham); 41 patients
were non-responders to vaccination. Seventeen patients had pos-
itive anti-HCV antibodies, and in 15 of them HCV-RNA could be
detected by PCR. Laboratory data of the patients included in this
study are given in Table 1.
Controls
Ninety-three healthy individuals recruited from a screening
program for thyroid diseases served as controls.
Processing of blood samples
Serum samples and heparinized peripheral venous blood was
collected at the same time from each patient using the vacutainer
system (Becton Dickinson). All sample handling was performed
under sterile conditions in a laminar air flow system in a dedicated
room separated from the area where PCR reactions were set up.
The recommended precautions to avoid contamination by PCR
product carryover and false-positive results were followed [10].
Peripheral blood mononuclear cells (PMNC) were separated by
buoyant density gradient centrifugation using Ficoll-Hypaque
(Pharmacia). The mononuclear cell fraction was aspirated and
washed six times with 30 ml of sterile 0.9% saline. This extensive
washing step has been shown in our laboratory to remove
serum-associated viral contamination from the PMNC fraction;
PCR from an aliquot of the last washing fluid was performed in
each patient and gave consistently negative results. Purified and
washed PMNC were counted, 2 to 5 3 106 PMNC were lysed in
500 ml 4 M guanidium isothiocyanate/1% 2-mercaptoethanol, and
stored at 270°C together with serum samples and an aliquot of
the last washing fluid.
Preparation of DNA and RNA for polymerase chain reaction
Preparation of DNA for HBV-PCR and RNA for HCV-PCR
and GBV-C/HGV-PCR from serum samples, PMNC and last
washing fluid of PMNC was done as described previously [9].
Oligonucleotide primers for HBV-DNA and HCV-RNA and
cycling conditions for nested PCR for HBV and HCV were the
same as described [9].
Reverse transcription was performed with RNA from 7 ml
serum or last washing fluid or from 1 3 105 PMNC, 5 3 reverse
transcription buffer (Cetus, USA) 200 nmol Dithiothreitol (Gibco
BRL, Life Technologies, Gaithersburg, PA, USA), 10 pmol dNTP
(Cetus) each, 100 pmol random hexamer primer [pd(N)6, Phar-
macia, Uppsala, Sweden], 20 U RNAsin (Promega) and 200 U
M-MLV RT (Moloney murine leukemia virus reverse transcrip-
tase, Gibco, NY, USA) in 20 ml volume for one hour at 37°C.
After a denaturation step at 99°C for 10 minutes 30 ml of master
mix for the first round PCR containing 10 3 PCR buffer, 5 pmol
dNTP each, 40 pmol each of outer primers (GB-C-sl and GB-C-
al) [4] and 1 U Taq polymerase (Cetus) was added. The cycling
protocol was as follows: two minutes 95°C, then 35 cycles of 15
seconds 94°C, 30 seconds 50°C and 30 seconds 72°C. One micro-
liter of the first PCR reaction was then transferred to a second
tube containing 10 3 PCR buffer, 4 pmol dNTP each, 40 pmol of
inner primers each (GB-C.5-sl and GB-C.5-al) [4] and 1 U Taq
polymerase in a total volume of 100 ml. The cycling protocol was
the same as for the first PCR. The amplified DNA product of 127
bp length was analyzed on a 1% agarose gel after staining with
ethidium bromide. The specifity of the product was verified by
hybridization to an internal digoxigenin-labeled oligonucleotide
probe (59-AGG-CGG-AGT-GCG-AGA-GAT-TGG-CCG-GC-
39) after transfer to a nylon membrane. In every PCR run, two
reagent controls, two positive and two negative samples were
included. All samples were run in duplicate from the beginning of
the extraction procedure until gel analysis, and only congruent
results were accepted.
Anti-E2 antibodies
A commercially available ELISA (Enzymun-Test Anti-HGenv,
Boehringer Mannheim, Germany) detecting serum antibodies
against the envelope antigen E2 of GBV-C/HGV was used [11].
Table 1. Clinical data and liver function tests of patients undergoing chronic hemodialysis
Patients with evidence for present
GBV-C/HGV infection
Patients without evidence for present
GBV-C/HGV infection
PGBV-C/HGV-RNA1
Anti-E21,
GBV-C/HGV-RNA2
Anti-E22,
GBV-C/HGV-RNA2
Number of patients 16 24 79
Gender male, female 7m, 9f 15m, 9f 62m, 41f NS
Age years 50 6 17 53 6 14 54 6 18 NS
Duration of hemodialysis months 46 6 43 30 6 27 35 6 31 NS
AST U/liter 10 6 15 9 6 10 9 6 6 NS
ALT U/liter 10 6 11 9 6 7 10 6 7 NS
gGT U/liter 23 6 30 51 6 122 34 6 65 NS
AP U/liter 157 6 79 148 6 79 142 6 100 NS
CHE kU/liter 3.6 6 1.4 4.3 6 1.2 3.8 6 1.2 NS
Bilirubin mg/dl 0.5 6 0.2 0.5 6 0.2 0.5 6 0.2 NS
Albumin g/liter 41 6 4 42 6 4 42 6 5 NS
Number of patients transfused 11 (69%) 13 (54%) 31 (39%) NS
Number of blood units given 9 6 16 8 6 21 4 6 10 , 0.05
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RESULTS
GBV-C/HGV-RNA in serum
We found GBV-C/HGV-RNA in 16 of 119 patients on chronic
hemodialysis (13%); this was significantly higher than the 2
positive individuals found in 93 healthy controls (2%; P 5 0.014;
Table 2). None of the GBV-C/HGV-RNA1 patients was co-
infected with HBV as judged by HBsAg and HBV-DNA (Table
1); 2 of the 16 GBV-C/HGV-RNA1 patients (13%) were co-
infected with HCV (anti-HCV1, HCV-RNA1; Table 2).
GBV-C/HGV-RNA in peripheral blood mononuclear cells
GBV-C/HGV-RNA was detected in PMNC of 6 out of 16
patients with GBV-C/HGV-RNA present in serum (38%; Table
2). In addition, we identified 2 serum GBV-C/HGV-RNA2
patients in whom GBV-C/HGV-RNA could be demonstrated in
PMNC only.
Anti-E2 envelope protein
In 26 patients (22%) anti-E2 were found in serum, and in 24 of
those patients GBV-C/HGV-RNA was negative. Two other pa-
tients were concomitantly positive for GBV-C/HGV-RNA and
anti-E2 in the group of 16 GBV-C/HGV-RNA1 patients. Two
additional patients, who were GBV-C/HGV-RNA1 in PMNC but
not in serum, were negative for anti-E2. Seventy-nine patients
were negative for both GBV-C/HGV-RNA and anti-E2. The
prevalence of anti-E2 in hemodialysis patients (26 of 119 patients;
22%) was not different as compared to healthy controls (12 of 93
healthy controls; 13%; P 5 0.13).
Clinical correlations
We compared clinical features of patients positive for GBV-C/
HGV-RNA in serum with those of patients without evidence for
GBV-C/HGV-infection (Table 1). We found no difference in the
mean duration of hemodialysis between those two groups. Pa-
tients with past or present contact to GBV-C/HGV had received
more units of blood than patients without evidence for GBV-C/
HGV infection (P , 0.05; Table 1). Only one of the GBV-C/
HGV-RNA1 patients had elevated aminotransferases; however,
this patient was also co-infected with HCV. Two additional
HCV1 but HGV2 patients had moderately elevated ALT levels.
There was no significant difference in markers of cholestasis, such
as alkaline phosphatase and gGT or in markers of liver synthesis
(albumin and pseudocholinesterase) or bilirubin between dialysis
patients positive for GBV-C/HGV-RNA or positive for anti-E2 or
negative for markers of GBV-C/HGV infection. No other labo-
ratory differences were found between these three groups. We
found a significant association of anti-HCV positivity with mark-
ers of past or present GBV-C/HGV infection (GBV-C/HGV-
RNA1 or anti-E21) (x2-test, P 5 0.003); however, there was no
association of past contact to hepatitis B virus (anti-HBc1) with
past or present contact to GBV-C/HGV (x2-test, P 5 0.554).
DISCUSSION
In the present study we showed a high prevalence of exposure
of patients on chronic hemodialysis to GBV-C/HGV: GBV-C/
HGV-RNA as well as anti-E2, indicating past contact to GBV-C/
HGV, were higher than found in healthy control individuals. In
addition, detection of GBV-C/HGV-RNA in PMNC disclosed
some patients as infected who had neither GBV-C/HGV-RNA
nor anti-E2 in serum.
GBV-C/HGV is assumed to be parenterally transmitted [12]
and patients on chronic hemodialysis constitute a group at risk for
such infection. An increased prevalence for GBV-C/HGV in
patients on chronic hemodialysis as compared to local control
population has been demonstrated by several groups [7, 13–18].
This increased prevalence was also observed in our patient
population, in which 13% were GBV-C/HGV-RNA1 as com-
pared to 2% of healthy local controls. In this respect GBV-C/
HGV is very similar to other parenterally transmitted hepatitis
viruses, such as HBV or HCV, which have also an increased
prevalence in dialysis patients [1, 9, 19].
There seems to be a wide range of GBV-C/HGV infection in
hemodialysis patients among different countries: available data
from Indonesia (55%) [15] and France (57%) [14] show a high
prevalence of GBV-C/HGV-RNA, whereas it was reported to be
low in Japan (3 to 10%) [13, 16] and Germany (5 to 7%) [7, 17].
Our data from Austria and recently published data from Italy
(19%) [18] indicate a similar relatively low prevalence of GBV-
C/HGV-RNA as opposed to France or Indonesia. Similar country
specific differences in prevalence have also been observed for
hepatitis B and C [1, 20]. In Indonesia the high prevalence of
GBV-C/HGV-RNA in patients on chronic hemodialysis corre-
sponded to a high prevalence of HCV-RNA (76%) [21] and
HBsAg (7%) [21]. Countries with low prevalence of GBV-C/
HGV-RNA such as Japan (10%) also had a relatively low
prevalence of anti-HCV (38%) [22] and HBsAg (1.6%) [23] in
dialysis patients. Similarly, in our patient population there was a
relatively low prevalence of GBV-C/HGV-RNA (13%), which
corresponded to a low prevalence of HCV-RNA (15%) and
HBsAg (0%).
GBV-C/HGV genome can be detected in PMNC [8]. In this
respect GBV-C/HGV is similar to HBV and HCV for which
transcription and replication in PMNC has been described [24,
25]. We found GBV-C/HGV-RNA in 8 of 119 patients on chronic
hemodialysis (7%), which is similar to the positivity rate of PMNC
for HBV-DNA (6%) or HCV-RNA (9%) as described previously
by our group [9]. More than a third of the patients positive for
GBV-C/HGV-RNA in serum (28%) also had GBV-C/HGV-RNA
in their PMNC. In addition, we identified 2 patients who were
negative for GBV-C/HGV-RNA in serum in whom GBV-C/
HGV-RNA could be demonstrated in their PMNC only; those
patients were also anti-E2 negative. Thus, testing for GBV-C/
HGV-RNA in PMNC in addition to serum is a more sensitive
Table 2. Prevalence of GBV-C/HGV in serum in relation to presence
of HBV and HCV in serum and of GBV-C/HGV-RNA in PMNC
GBV-C/HGV
serum 1
GBV-C/HGV
serum 2 Total
HBV serum 1 0 2 2
HBV serum 2 16 101 117
Total 16 103 119
HCV serum 1 2 13 15
HCV serum 2 14 90 104
Total 16 103 119
PMNC 1 6 2 8
PMNC 2 10 101 111
Total 16 103 119
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approach than serum testing alone. By searching for GBV-C/
HGV in PMNC, occult infection with this virus might be uncov-
ered.
Recently, an antibody test system to detect antibodies to the
envelope protein (E2) of GBV-C/HGV has been described [11].
In general anti-E21 patients have lost GBV-C/HGV-RNA from
serum and the presence of anti-E2 is thought to indicate resolved
infection. Thus, the combined detection of GBV-C/HGV-RNA
and anti-E2 is necessary to define the overall exposure to GBV-
C/HGV. Only 22% of our patients were positive for anti-E2. This
is less than the 41% reported for drug users [11], but more than
8.5% found by others in dialysis patients [17]. We confirm in this
patient population the observation that the presence of anti-E2 is
associated with the loss of detectable GBV-C/HGV-RNA. Only 2
of 26 patients with anti-E2 had GBV-C/HGV-RNA demonstrable
in serum. The percentage of patients positive for both GBV-C/
HGV-RNA and anti-E2 (7.6%) compares well to that reported by
others [11, 17], but contrasts to a report describing GBV-C/HGV-
RNA and anti-E2 antibodies as mutually exclusive [26]. Combin-
ing the numbers of GBV-C/HGV-RNA1 with that of anti-E21
patients gives a more accurate picture of exposure to hepatitis G
virus in this population: 34% of our patients on chronic hemodi-
alysis had contact to the virus. This is considerably more than
reported in another dialysis population in Central Europe [17] for
which the combined prevalence of GBV-C/HGV-markers was
only 7.8%. That difference in prevalence in GBV-C/HGV-mark-
ers indicates a high variability in exposure to the virus even in
nearby geographic areas as previously reported for HBV and
HCV infection [23] and makes it necessary to determine the local
prevalence of GBV-C/HGV. The prevalence of anti-E2 among
dialysis patients was not significantly different from that among
healthy population, but the prevalence of GBV-C/HGV-RNA was
significantly higher among dialysis patients. The impaired immune
response in dialysis patients [27] could be the reason for the
higher percentage of active HGV infections.
In accordance with the reports of others [13, 18], GBV-C/HGV
positive patients in our chronic hemodialysis program had no
evidence for liver damage as judged by elevated aminotrans-
ferases. Only one of our GBV-C/HGV-RNA1 patients had
increased AST levels, which we attributed to his co-infection with
HCV. Furthermore, we could not demonstrate an association of
the duration of hemodialysis with GBV-C/HGV-status (GBV-C/
HGV-RNA1 or anti-E21). However, as a possible hint to the
mode of transmission of GBV-C/HGV we and others [14] could
demonstrate that the group of patients with GBV-C/HGV contact
had received significantly more units of blood. This mode of
transmission is further suggested by a significant association
between contact to HCV and GBV-C/HGV.
In summary, patients on chronic hemodialysis have a high
prevalence of markers for present or past infection with hepatitis
G virus. Additional determination of anti-E2 allows us to draw a
more complete picture of contact to GBV-C/HGV than testing for
GBV-C/HGV-RNA alone. GBV-C/HGV infection does not in-
duce elevation of aminotransferases in this patient group, and no
specific clinical features distinguishing GBV-C/HGV-RNA1
from GBV-C/HGV-RNA2 patients could be identified. The
clinical importance of this infection remains to be established.
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